IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options.
IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.
Company Details
- Employees
- 13
- Founded
- -
- Address
- Pennyfoot Street, Biocity,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.isomab.bio/
- Keywords
- jobs.
- HQ
- Nottingham, England
Isomab Ltd Questions
Isomab Ltd's website is https://www.isomab.bio/
Isomab Ltd's LinkedIn profile is https://uk.linkedin.com/company/isomab-ltd
Isomab Ltd has
13 employees.
View email and phone details for 13
employees at Isomab Ltd.
Isomab Ltd's industry is
Biotechnology Research
Isomab Ltd's top competitors are
Ono Pharmaceutical Co., Ltd.,
Science Creates,
Triana Biomedicines,
Scvc,
Obn (Uk) Ltd,
Imspex Diagnostics Ltd,
Molecure,
Broadview Ventures Inc,
Exonate Limited,
Scarlet Therapeutics Ltd.
Isomab Ltd's categories are Biotechnology Research
Isomab Ltd's founding year is 2022
